These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8246699)

  • 21. Incorporating risk attitude into Markov-process decision models: importance for individual decision making.
    Cher DJ; Miyamoto J; Lenert LA
    Med Decis Making; 1997; 17(3):340-50. PubMed ID: 9219195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthy year equivalents versus quality-adjusted life years: the debate continues.
    Towers I; Spencer A; Brazier J
    Expert Rev Pharmacoecon Outcomes Res; 2005 Jun; 5(3):245-54. PubMed ID: 19807594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Life expectancy, comorbidity, and quality of life. A framework of reference for medical decisions.
    Bennahum DA; Forman WB; Vellas B; Albarede JL
    Clin Geriatr Med; 1997 Feb; 13(1):33-53. PubMed ID: 8995099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
    Desch CE; Hillner BE; Smith TJ; Retchin SM
    J Clin Oncol; 1993 Apr; 11(4):777-82. PubMed ID: 8478671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A utility-theoretic model for QALYs and willingness to pay.
    Klose T
    Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
    Long EF; Swain GW; Mangi AA
    Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores.
    Stiggelbout AM; Kiebert GM; Kievit J; Leer JW; Stoter G; de Haes JC
    Med Decis Making; 1994; 14(1):82-90. PubMed ID: 8152360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A criticism of healthy-years equivalents.
    Wakker P
    Med Decis Making; 1996; 16(3):207-14. PubMed ID: 8818117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.
    Brown GC; Brown MM; Campanella J; Beauchamp GR
    Am J Ophthalmol; 2005 Oct; 140(4):679-87. PubMed ID: 16226519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence.
    Bleichrodt H; Johannesson M
    Med Decis Making; 1997; 17(1):21-32. PubMed ID: 8994148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of using electron beam computed tomography to identify patients at risk for clinical coronary artery disease.
    O'Malley PG; Greenberg BA; Taylor AJ
    Am Heart J; 2004 Jul; 148(1):106-13. PubMed ID: 15215799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome.
    Brown MM; Brown GC; Brown HC; Peet J; Roth Z
    Arch Ophthalmol; 2009 Feb; 127(2):146-52. PubMed ID: 19204231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysing risk attitudes to time.
    Oliver A; Cookson R
    Health Econ; 2010 Jun; 19(6):644-55. PubMed ID: 19424992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multivariate risk preferences in the quality-adjusted life year model.
    Attema AE; Frasch JJ; L'Haridon O
    Health Econ; 2022 Feb; 31(2):382-398. PubMed ID: 34796588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
    Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
    Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health related utility measurement: an introduction.
    Bakker C; van der Linden S
    J Rheumatol; 1995 Jun; 22(6):1197-9. PubMed ID: 7674256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
    Guadagnolo BA; Punglia RS; Kuntz KM; Mauch PM; Ng AK
    J Clin Oncol; 2006 Sep; 24(25):4116-22. PubMed ID: 16943528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.